SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). The conference is being held at The Waldorf Astoria New York hotel in New York City.
"This is an exciting time at MabVax with preparations underway to begin Phase I clinical trials with our fully human antibody product HuMab-5B1 as both a therapeutic agent and a new generation PET scan cancer imaging agent," said David Hansen, MabVax's President and Chief Executive Officer. "We anticipate reporting an interim safety assessment and determination of a maximum tolerated dose in the therapeutics trial and an initial set of disease images in the imaging trial by mid-year 2016. These near-term interim data could provide additional validation for our proprietary approach to immune-oncology. We look forward to updating investors on our progress and upcoming milestones at this well-attended conference."
A live webcast of the presentation will be available on Company's website at http://www.mabvax.com/investor-relations.php. A replay of the presentation will be available for 90 days.
About BIO CEO & Investor Conference:
The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. The event features plenary sessions, fireside chats, business roundtables, therapeutic workshops, company presentations and One-on-One PartneringTM meetings.
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. In December 2015, MabVax received authorization from the U.S. Food and Drug Administration (FDA) to proceed with the Company's fully human antibody product, HuMab-5B1, in a Phase I trial as a therapeutic treatment for patients with pancreatic cancer. MabVax plans to begin this Phase I trial in the first quarter of 2016. On February 1, 2016, MabVax announced that it had received authorization from the FDA to proceed with a second Phase I trial for 89Zr-HuMab-5B1, a next-generation PET imaging agent for pancreatic cancer. MabVax also has the exclusive license to several therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials. Additional information is available at www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's two authorizations to proceed with Phase I clinical trials and product development pipeline. We have no assurance that all of the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Senior Vice President
SOURCE MabVax Therapeutics Holdings, Inc.